Radiopharm Theranostics Limited - American Depositary Shares (RADX)
RADX moved a median of -0.53% 30 minutes after news, and 0.00% by the close. How RADX actually reacts to news — the realized, point-in-time move the market made, measured across 75 labeled events over the last three years with zero look-ahead.
RADX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 24% | 58 |
| 30-min | -0.53% | 31% | 70 |
| 60-min | -0.84% | 37% | 70 |
| to close | 0.00% | 48% | 69 |
| Middle 50% of RADX reactions | -1.99% to +1.16% |
|---|---|
| Median reaction (30-min) | -0.53% |
| Measured reactions | 75 |
Half of all Radiopharm Theranostics Limited - American Depositary Shares news events land between -1.99% and +1.16% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when RADX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RADX's baseline. Nothing else.
Recent RADX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K Radiopharm Theranostics For: Oct 20 | SEC filing · Form 6-K | SEC EDGAR | — | — | |
| Form 6-K Radiopharm Theranostics For: Oct 05 | SEC filing · Form 6-K | SEC EDGAR | +0.72% | -8.63% | |
| Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101 | Press release | GlobeNewswire | +0.72% | -8.63% | |
| Form 6-K Radiopharm Theranostics For: Oct 01 | SEC filing · Form 6-K | SEC EDGAR | -9.67% | -4.52% | |
| Form 20-F Radiopharm Theranostics For: Jun 30 | SEC filing · Form 20-F | SEC EDGAR | — | +2.53% | |
| Form 6-K Radiopharm Theranostics For: Sep 30 | SEC filing · Form 6-K | SEC EDGAR | -9.38% | +1.25% | |
| Form EFFECT Radiopharm Theranostics | SEC filing · Form EFFECT | SEC EDGAR | -3.01% | -5.31% | |
| Form 6-K Radiopharm Theranostics For: Sep 22 | SEC filing · Form 6-K | SEC EDGAR | +1.20% | -1.20% | |
| Form 6-K Radiopharm Theranostics For: Sep 14 | SEC filing · Form 6-K | SEC EDGAR | -1.99% | +0.00% | |
| Form F-3 Radiopharm Theranostics | SEC filing · Form F-3 | SEC EDGAR | -1.99% | +0.00% | |
| Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting | Press release | GlobeNewswire | -1.99% | +0.00% | |
| Form 6-K Radiopharm Theranostics For: Sep 11 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -3.88% | |
| Form 6-K Radiopharm Theranostics For: Sep 09 | SEC filing · Form 6-K | SEC EDGAR | +1.42% | -1.89% | |
| Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma | Press release | GlobeNewswire | +1.42% | -1.89% | |
| Form 6-K Radiopharm Theranostics For: Aug 28 | SEC filing · Form 6-K | SEC EDGAR | -1.63% | -2.03% | |
| Form 6-K Radiopharm Theranostics For: Aug 27 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +3.67% | |
| Form 6-K Radiopharm Theranostics For: Aug 26 | SEC filing · Form 6-K | SEC EDGAR | -2.14% | -6.45% | |
| Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors | Press release | GlobeNewswire | -2.14% | -6.45% | |
| Form 6-K Radiopharm Theranostics For: Aug 20 | SEC filing · Form 6-K | SEC EDGAR | -2.86% | -6.53% | |
| Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial | Press release | GlobeNewswire | -2.86% | -6.53% | |
| Form 6-K Radiopharm Theranostics For: Aug 17 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +4.30% | |
| Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases | Press release | GlobeNewswire | +0.00% | +4.30% | |
| Form 6-K Radiopharm Theranostics For: Aug 13 | SEC filing · Form 6-K | SEC EDGAR | -1.79% | -5.36% | |
| Form 6-K Radiopharm Theranostics For: Aug 03 | SEC filing · Form 6-K | SEC EDGAR | -1.97% | +2.30% | |
| Form 6-K Radiopharm Theranostics For: Jul 24 | SEC filing · Form 6-K | SEC EDGAR | -1.97% | +2.30% | |
| Form 6-K Radiopharm Theranostics For: Jul 31 | SEC filing · Form 6-K | SEC EDGAR | +3.33% | +5.00% | |
| Radiopharm Theranostics Reports Business Update | Press release | GlobeNewswire | +3.33% | +5.00% | |
| Form 6-K Radiopharm Theranostics For: Jul 28 | SEC filing · Form 6-K | SEC EDGAR | -4.11% | -8.06% | |
| Form 6-K Radiopharm Theranostics For: Jul 27 | SEC filing · Form 6-K | SEC EDGAR | -0.43% | +12.27% | |
| Form 6-K Radiopharm Theranostics For: Jul 24 | SEC filing · Form 6-K | SEC EDGAR | +2.09% | +23.69% | |
| Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan | Press release | GlobeNewswire | +2.09% | +23.69% | |
| Form 6-K Radiopharm Theranostics For: Jul 22 | SEC filing · Form 6-K | SEC EDGAR | — | — | |
| Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy | Press release | GlobeNewswire | — | — | |
| Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases | Press release | GlobeNewswire | — | — | |
| Form 6-K Radiopharm Theranostics For: Jul 03 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +0.00% | |
| Form 6-K Radiopharm Theranostics For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -0.72% | +0.72% | |
| Form 6-K Radiopharm Theranostics For: Jun 03 | SEC filing · Form 6-K | SEC EDGAR | — | +0.22% | |
| Radiopharm Theranostics Reports Business Update | Press release | GlobeNewswire | +0.22% | -2.06% | |
| Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026 | Press release | GlobeNewswire | -2.96% | +3.90% | |
| Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial | Press release | GlobeNewswire | — | +3.23% | |
| Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S. | Press release | GlobeNewswire | -0.44% | +1.64% | |
| Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer | Press release | GlobeNewswire | +0.48% | +1.19% | |
| Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases | Press release | GlobeNewswire | -1.30% | -10.39% | |
| Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01) | Press release | GlobeNewswire | — | +2.85% | |
| Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates | Press release | GlobeNewswire | +3.66% | +2.44% | |
| Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream | Press release | GlobeNewswire | +0.70% | +0.40% | |
| RAD Increases Ownership in Radiopharm Ventures to 87.5% | Press release | GlobeNewswire | +0.00% | -0.19% | |
| Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases | Press release | GlobeNewswire | +5.04% | -24.56% | |
| Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer | Press release | GlobeNewswire | -5.84% | -6.93% | |
| Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases | Press release | GlobeNewswire | -2.81% | -2.48% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RADX section they belong to.
Where else RADX is measured.
RADX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Radiopharm Theranostics Limited - American Depositary Shares's median reaction calculated?
Every labeled RADX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 75 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 31% of RADX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RADX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.